Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Spinal Muscular Atrophy Medicine Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Spinal Muscular Atrophy Medicine Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 LMI-070
      • 1.3.3 ND-602
      • 1.3.4 NT-1654
      • 1.3.5 Nusinersen
      • 1.3.6 NXD-30001
      • 1.3.7 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Spinal Muscular Atrophy Medicine Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Spinal Muscular Atrophy Medicine Market Size
      • 2.1.1 Global Spinal Muscular Atrophy Medicine Revenue 2014-2025
      • 2.1.2 Global Spinal Muscular Atrophy Medicine Sales 2014-2025
    • 2.2 Spinal Muscular Atrophy Medicine Growth Rate by Regions
      • 2.2.1 Global Spinal Muscular Atrophy Medicine Sales by Regions 2014-2019
      • 2.2.2 Global Spinal Muscular Atrophy Medicine Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers
      • 3.1.1 Spinal Muscular Atrophy Medicine Sales by Manufacturers 2014-2019
      • 3.1.2 Spinal Muscular Atrophy Medicine Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Spinal Muscular Atrophy Medicine Revenue by Manufacturers (2014-2019)
      • 3.2.2 Spinal Muscular Atrophy Medicine Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Spinal Muscular Atrophy Medicine Market Concentration Ratio (CR5 and HHI)
    • 3.3 Spinal Muscular Atrophy Medicine Price by Manufacturers
    • 3.4 Key Manufacturers Spinal Muscular Atrophy Medicine Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
    • 3.6 Key Manufacturers Spinal Muscular Atrophy Medicine Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 LMI-070 Sales and Revenue (2014-2019)
      • 4.1.2 ND-602 Sales and Revenue (2014-2019)
      • 4.1.3 NT-1654 Sales and Revenue (2014-2019)
      • 4.1.4 Nusinersen Sales and Revenue (2014-2019)
      • 4.1.5 NXD-30001 Sales and Revenue (2014-2019)
      • 4.1.6 Others Sales and Revenue (2014-2019)
    • 4.2 Global Spinal Muscular Atrophy Medicine Sales Market Share by Type
    • 4.3 Global Spinal Muscular Atrophy Medicine Revenue Market Share by Type
    • 4.4 Spinal Muscular Atrophy Medicine Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Spinal Muscular Atrophy Medicine Sales by Application

    6 United States

    • 6.1 United States Spinal Muscular Atrophy Medicine Breakdown Data by Company
    • 6.2 United States Spinal Muscular Atrophy Medicine Breakdown Data by Type
    • 6.3 United States Spinal Muscular Atrophy Medicine Breakdown Data by Application

    7 European Union

    • 7.1 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Company
    • 7.2 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Type
    • 7.3 European Union Spinal Muscular Atrophy Medicine Breakdown Data by Application

    8 China

    • 8.1 China Spinal Muscular Atrophy Medicine Breakdown Data by Company
    • 8.2 China Spinal Muscular Atrophy Medicine Breakdown Data by Type
    • 8.3 China Spinal Muscular Atrophy Medicine Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Company
    • 9.2 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Type
    • 9.3 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Application
    • 9.4 Rest of World Spinal Muscular Atrophy Medicine Breakdown Data by Countries
      • 9.4.1 Rest of World Spinal Muscular Atrophy Medicine Sales by Countries
      • 9.4.2 Rest of World Spinal Muscular Atrophy Medicine Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Astellas Pharma Inc.
      • 10.1.1 Astellas Pharma Inc. Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.1.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.1.5 Astellas Pharma Inc. Recent Development
    • 10.2 AveXis, Inc.
      • 10.2.1 AveXis, Inc. Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.2.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.2.5 AveXis, Inc. Recent Development
    • 10.3 Bioblast Pharma Ltd.
      • 10.3.1 Bioblast Pharma Ltd. Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.3.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.3.5 Bioblast Pharma Ltd. Recent Development
    • 10.4 Cytokinetics, Inc. 24
      • 10.4.1 Cytokinetics, Inc. 24 Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.4.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.4.5 Cytokinetics, Inc. 24 Recent Development
    • 10.5 F. Hoffmann-La Roche Ltd.
      • 10.5.1 F. Hoffmann-La Roche Ltd. Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.5.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.5.5 F. Hoffmann-La Roche Ltd. Recent Development
    • 10.6 Genethon
      • 10.6.1 Genethon Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.6.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.6.5 Genethon Recent Development
    • 10.7 Genzyme Corporation
      • 10.7.1 Genzyme Corporation Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.7.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.7.5 Genzyme Corporation Recent Development
    • 10.8 GMP-Orphan SAS
      • 10.8.1 GMP-Orphan SAS Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.8.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.8.5 GMP-Orphan SAS Recent Development
    • 10.9 Ionis Pharmaceuticals, Inc.
      • 10.9.1 Ionis Pharmaceuticals, Inc. Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.9.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.9.5 Ionis Pharmaceuticals, Inc. Recent Development
    • 10.10 Longevity Biotech, Inc
      • 10.10.1 Longevity Biotech, Inc Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Spinal Muscular Atrophy Medicine
      • 10.10.4 Spinal Muscular Atrophy Medicine Product Introduction
      • 10.10.5 Longevity Biotech, Inc Recent Development
    • 10.11 Neurodyn Inc.
    • 10.12 Neurotune AG
    • 10.13 Novartis AG
    • 10.14 Sarepta Therapeutics, Inc.
    • 10.15 Voyager Therapeutics, Inc.
    • 10.16 Vybion, Inc.
    • 10.17 WAVE Life Sciences Ltd.

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Spinal Muscular Atrophy Medicine Sales Channels
      • 11.2.2 Spinal Muscular Atrophy Medicine Distributors
    • 11.3 Spinal Muscular Atrophy Medicine Customers

    12 Market Forecast

    • 12.1 Global Spinal Muscular Atrophy Medicine Sales and Revenue Forecast 2019-2025
    • 12.2 Global Spinal Muscular Atrophy Medicine Sales Forecast by Type
    • 12.3 Global Spinal Muscular Atrophy Medicine Sales Forecast by Application
    • 12.4 Spinal Muscular Atrophy Medicine Forecast by Regions
      • 12.4.1 Global Spinal Muscular Atrophy Medicine Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Spinal Muscular Atrophy Medicine Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Spinal Muscular Atrophy Medicine is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Spinal Muscular Atrophy Medicine.

      This report studies the global market size of Spinal Muscular Atrophy Medicine, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Spinal Muscular Atrophy Medicine sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Astellas Pharma Inc.
      AveXis, Inc.
      Bioblast Pharma Ltd.
      Cytokinetics, Inc. 24
      F. Hoffmann-La Roche Ltd.
      Genethon
      Genzyme Corporation
      GMP-Orphan SAS
      Ionis Pharmaceuticals, Inc.
      Longevity Biotech, Inc
      Neurodyn Inc.
      Neurotune AG
      Novartis AG
      Sarepta Therapeutics, Inc.
      Voyager Therapeutics, Inc.
      Vybion, Inc.
      WAVE Life Sciences Ltd.

      Market Segment by Product Type
      LMI-070
      ND-602
      NT-1654
      Nusinersen
      NXD-30001
      Others

      Market Segment by Application
      Hospital
      Clinic
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Spinal Muscular Atrophy Medicine status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Spinal Muscular Atrophy Medicine manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Spinal Muscular Atrophy Medicine are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now